http://orcid.org/0000-0003-3450-6854
About the Authors
- Peter Rashkov
-
Affiliation School of Biosciences, University of Exeter, Exeter, United Kingdom
- Ian P. Barrett
-
Affiliation Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom
- Robert E. Beardmore
-
Affiliation School of Biosciences, University of Exeter, Exeter, United Kingdom
- Claus Bendtsen
-
* E-mail: Claus.Bendtsen@astrazeneca.com (CB); I.Gudelj@exeter.ac.uk (IG)
Affiliation Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom
- Ivana Gudelj
-
* E-mail: Claus.Bendtsen@astrazeneca.com (CB); I.Gudelj@exeter.ac.uk (IG)
Affiliation School of Biosciences, University of Exeter, Exeter, United Kingdom
Competing Interests
IPB and CB were employees of AstraZeneca at time of writing of the manuscript. This does not alter the authors’ adherence to PLOS policies on sharing data and materials.
Author Contributions
Conceptualization: IG CB IPB REB. Formal analysis: PR. Funding acquisition: IG REB. Methodology: PR IG IPB CB. Software: PR. Supervision: IG REB IPB CB. Writing – original draft: IG REB IPB CB PR.